Successful treatment of retroperitoneal infantile hemangioendothelioma with Kasabach-Merritt syndrome using steroid, alpha-interferon, and vincristine.

Abstract

Infantile hemangioendothelioma (IHE) is a rare benign vascular tumor with potentially life-threatening complications. Various therapeutic options have been recommended according to the site, extent, and behavior of the IHE. Because of the slow and unpredictable response to treatment with using a single drug in critically ill patients, there is a tendency to administer drugs in combination to treat this disease. Here, we report on a 1-month-old female infant who had a retroperitoneal IHE with Kasabach-Merritt syndrome and she was successfully treated with a combination of steroid, interferon-alpha, and vincristine.

• Authors: Hoi Soo Yoon, Jae Hee Lee, Hyung Nam Moon, Jong Jin Seo, Ho Joon Im, Hyun Woo Goo
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 31 Issue 12 Pg. 952-4 (Dec 2009) ISSN: 1536-3678 [Electronic] United States
• PMID: 19875968 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon-alpha
• Vincristine
• Methylprednisolone

Topics

• Diagnosis, Differential
• Disseminated Intravascular Coagulation (complications, drug therapy)
• Drug Therapy, Combination
• Female
• Hemangioendothelioma (drug therapy)
• Humans
• Infant, Newborn
• Interferon-alpha (therapeutic use)
• Methylprednisolone (therapeutic use)
• Retroperitoneal Neoplasms (drug therapy)
• Syndrome
• Treatment Outcome
• Vincristine (therapeutic use)